Oncosil Medical (ASX:OSL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Oncosil Medical (ASX:OSL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
OncoSil submits US Reimbursement Application (Updated)
OncoSil submits US Reimbursement Application
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report
OncoSil Medical reports FY26 revenue growth, reduced loss, key regulatory approvals, and commercial expansion
Change in substantial holding
Change in substantial shareholding from AEF
Application for quotation of securities - OSL
Investor Webinar Presentation
OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
OncoSil Medical secures FDA approval for OncoSil™ device to treat rare bile duct cancer in U.S.
Quarterly Activities/Appendix 4C Cash Flow Report
OncoSil Medical reports strong sales growth, key clinical and regulatory milestones, and $6.5M cash at Q4 FY26
New Independent Study Confirms OncoSil Dose Flexibility
Application for quotation of securities - OSL
OncoSil Medical Receives Saudi Arabia FDA Approval
OncoSil Medical gains Saudi FDA approval for OncoSil™ device with full reimbursement access
Application for quotation of securities - OSL
Investor Presentation
OSPREY Registry Abstract Accepted for EANM 2026 Congress
OncoSil Medical Completes Manufacturing Validation
OncoSil Medical Completes Manufacturing Validation and Establishes Scalable Australian Production
TRIPP-FFX Results Presented at ESMO GI 2026
OncoSil Medical Files for FDA Approval
OncoSil Medical files FDA HDE application for OncoSil™ device to treat distal cholangiocarcinoma
OncoSil Selected for Major European Pancreatic Cancer Study
OncoSil Medical joins major European pancreatic cancer consortium with cost-efficient PULSE trial
TRIPP-FFX Abstract Published on ESMO GI 2026 Website
Notice under ASX Listing Rule 3.10A
Publication verifies OncoSil strong localisation in pancreas
OncoSil Medical Launches Investor Hub
Change in substantial shareholding from AEF
TRIPP FFX accepted for oral presentation at ESMO GI 2026
US FDA HDE and TRIPP-FFX Study Presentation
OncoSil Medical Nears FDA Approval and Reports Positive TRIPP-FFX Trial Results
OncoSil progresses HDE with US FDA
OncoSil Medical Advances to Final FDA Review Stage for HDE Approval of OncoSil™ Device
TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints